Clinical features and prognosis of hepatocellular carcinoma with respect to pre-S deletion and basal core promoter mutations of hepatitis B virus Genotype C2

Journal of Medical Virology

Volumn 83, Issue 12, 2011, Pages 2088-2095

  Ryu, Han Jak ^a,b   Kim, Do Young ^a,b   Park, Jun Yong ^a,b   Chang, Hye Young ^a   Lee, Myoung Ha ^a,b   Han, Kwang Hyub ^a,b,c   Chon, Chae Yoon ^a,b   Ahn, Sang Hoon ^a,b,c  

^a Yonsei University College of Medicine   (South Korea)

^b Liver Cirrhosis Clinical Research Center   (South Korea)

^c Yonsei University   (South Korea)

Author keywords

Basal core promoter; Hepatitis B virus; Hepatocellular carcinoma; Pre S; Prognosis

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA FETOPROTEIN; ANTINEOPLASTIC AGENT; HEPATITIS B(E) ANTIGEN; VIRUS DNA;

ABLATION THERAPY; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BASAL CORE PROMOTER REGION; CANCER CHEMOTHERAPY; CANCER INVASION; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SIZE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CHEMOEMBOLIZATION; CLINICAL FEATURE; FEMALE; GENE DELETION; GENE MUTATION; GENOTYPE; HEPATITIS B VIRUS; HUMAN; KOREA; LIVER CELL CARCINOMA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; NUCLEOTIDE SEQUENCE; PORTAL VEIN THROMBOSIS; PRE S DELETION; PROGNOSIS; PROMOTER REGION; PROTEIN BLOOD LEVEL; RADIOFREQUENCY ABLATION; SURVIVAL RATE; VIRUS GENE;

ADOLESCENT; ADULT; CARCINOMA, HEPATOCELLULAR; DNA, VIRAL; FEMALE; GENOTYPE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MUTATION; PROGNOSIS; PROMOTER REGIONS, GENETIC; REPUBLIC OF KOREA; SEQUENCE ANALYSIS, DNA; SEQUENCE DELETION; SURVIVAL ANALYSIS; YOUNG ADULT;

HEPATITIS B VIRUS;

EID: 80054868018     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.22238     Document Type: Article

References (50)

1. Ahn SH, Han KH, Park JY, Lee CK, Kang SW, Chon CY, Kim YS, Park K, Kim DK, Moon YM. 2000. Association between hepatitis B virus infection and HLA-DR type in Korea. Hepatology 31: 1371-1373.
2. Ahn SH, Yuen L, Han K, Littlejohn M, Chang HY, Damerow H, Ayres A, Heo J, Locarnini S, Revill PA. 2010. Molecular and clinical characteristics of hepatitis B virus in Korea. J Med Virol 82: 1126-1134.
3. Baumert TF, Rogers SA, Hasegawa K, Liang TJ. 1996. Two core promotor mutations identified in a hepatitis B virus strain associated with fulminant hepatitis result in enhanced viral replication. J Clin Invest 98: 2268-2276.
4. Bock CT, Tillmann HL, Manns MP, Trautwein C. 1999. The pre-S region determines the intracellular localization and appearance of hepatitis B virus. Hepatology 30: 517-525.
5. Buckwold VE, Xu Z, Chen M, Yen TS, Ou JH. 1996. Effects of a naturally occurring mutation in the hepatitis B virus basal core promoter on precore gene expression and viral replication. J Virol 70: 5845-5851.
6. Chan HL, Hussain M, Lok AS. 1999. Different hepatitis B virus genotypes are associated with different mutations in the core promoter and precore regions during hepatitis B e antigen seroconversion. Hepatology 29: 976-984.
7. Chen BF, Liu CJ, Jow GM, Chen PJ, Kao JH, Chen DS. 2006. High prevalence and mapping of pre-S deletion in hepatitis B virus carriers with progressive liver diseases. Gastroenterology 130: 1153-1168.
8. Chen C, Hung C, Lee C, Hu T, Wang J, Lu S, Changchien C. 2007. Pre-S deletion and complex mutations of hepatitis B virus related to advanced liver disease in HBeAg-negative patients. Gastroenterology 133: 1466-1474.
9. Chen C, Changchien C, Lee C, Hung C, Hu T, Wang J, Lu S. 2008. Combined mutations in pre-s/surface and core promoter/precore regions of hepatitis B virus increase the risk of hepatocellular carcinoma: A case-control study. J Infect Dis 198: 1634-1642.
10. Chisari FV, Filippi P, Buras J, McLachlan A, Popper H, Pinkert CA, Palmiter RD, Brinster RL. 1987. Structural and pathological effects of synthesis of hepatitis B virus large envelope polypeptide in transgenic mice. Proc Natl Acad Sci USA 84: 6909-6913.
11. Choi JW, Ahn SH, Park JY, Chang HY, Kim JK, Baatarkhuu O, Kim do Y, Han KH, Chon CY. 2009. Hepatitis B e antigen-negative mutations in the precore and core promoter regions in Korean patients. J Med Virol 81: 594-601.
12. Ferrari C, Penna A, DegliAntoni A, Fiaccadori F. 1988. Cellular immune response to hepatitis B virus antigens. An overview. J Hepatol 7: 21-33.
13. Gilles PN, Guerrette DL, Ulevitch RJ, Schreiber RD, Chisari FV. 1992. HBsAg retention sensitizes the hepatocyte to injury by physiological concentrations of interferon-gamma. Hepatology 16: 655-663.
14. Gomaa AI, Khan SA, Toledano MB, Waked I, Taylor-Robinson SD. 2008. Hepatocellular carcinoma: Epidemiology, risk factors and pathogenesis. World J Gastroenterol 14: 4300-4308.
15. Hagen TM, Huang S, Curnutte J, Fowler P, Martinez V, Wehr CM, Ames BN, Chisari FV. 1994. Extensive oxidative DNA damage in hepatocytes of transgenic mice with chronic active hepatitis destined to develop hepatocellular carcinoma. Proc Natl Acad Sci USA 91: 12808-12812.
16. Han K, Ahn SH. 2005. How to predict HCC development in patients with chronic B viral liver disease? Intervirology 48: 23-28.
17. Holomn J, Glasa J. 2009. EASL clinical practice guidelines. J Hepatol 51: 821-822.
18. Hsieh Y, Su I, Wang H, Chang W, Lei H, Lai M, Huang W. 2004. Pre-S mutant surface antigens in chronic hepatitis B virus infection induce oxidative stress and DNA damage. Carcinogenesis 25: 2023-2032.
19. Huang SN, Chisari FV. 1995. Strong, sustained hepatocellular proliferation precedes hepatocarcinogenesis in hepatitis B surface antigen transgenic mice. Hepatology 21: 620-626.
20. Kao J, Chen P, Lai M, Chen D. 2003. Basal core promoter mutations of hepatitis B virus increase the risk of hepatocellular carcinoma in hepatitis B carriers. Gastroenterology 124: 327-334.
21. Kay A, Zoulim F. 2007. Hepatitis B virus genetic variability and evolution. Virus Res 127: 164-176.
22. Kidd AH, Kidd-Ljunggren K. 1996. A revised secondary structure model for the 3'-end of hepatitis B virus pregenomic RNA. Nucleic Acids Res 24: 3295-3301.
23. Kim SR, Kudo M, Hino O, Han KH, Chung YH, Lee HS. 2008a. Epidemiology of hepatocellular carcinoma in Japan and Korea. A review. Oncology 75: 13-16.
24. Kim SU, Han KH, Nam CM, Park JY, Kim DY, Chon CY, Ahn SH. 2008b. Natural history of hepatitis B virus-related cirrhotic patients hospitalized to control ascites. J Gastroenterol Hepatol 23: 1722-1727.
25. Kim JK, Chang HY, Lee JM, Baatarkhuu O, Yoon YJ, Park JY, Kim DY, Han K, Chon CY, Ahn SH. 2009. Specific mutations in the enhancer II/core promoter/precore regions of hepatitis B virus subgenotype C2 in Korean patients with hepatocellular carcinoma. J Med Virol 81: 1002-1008.
26. Laskus T, Rakela J, Tong MJ, Nowicki MJ, Mosley JW, Persing DH. 1994. Naturally occurring hepatitis B virus mutants with deletions in the core promoter region. J Hepatol 20: 837-841.
27. Lauer U, Weiss L, Hofschneider PH, Kekul AS. 1992. The hepatitis B virus pre-S/S(t) transactivator is generated by 3' truncations within a defined region of the S gene. J Virol 66: 5284-5289.
28. Li J, Buckwold VE, Hon MW, Ou JH. 1999. Mechanism of suppression of hepatitis B virus precore RNA transcription by a frequent double mutation. J Virol 73: 1239-1244.
29. Lin CL, Liu CH, Chen W, Huang WL, Chen PJ, Lai MY, Chen DS, Kao JH. 2007. Association of pre-S deletion mutant of hepatitis B virus with risk of hepatocellular carcinoma. J Gastroenterol Hepatol 22: 1098-1103.
30. Liu S, Zhang H, Gu C, Yin J, He Y, Xie J, Cao G. 2009. Associations between hepatitis B virus mutations and the risk of hepatocellular carcinoma: A meta-analysis. J Natl Cancer Inst 101: 1066-1082.
31. Meyer M, Caselmann WH, Schlter V, Schreck R, Hofschneider PH, Baeuerle PA. 1992. Hepatitis B virus transactivator MHBst: Activation of NF-kappa B, selective inhibition by antioxidants and integral membrane localization. EMBO J 11: 2991-3001.
32. Omata M, Ehata T, Yokosuka O, Hosoda K, Ohto M. 1991. Mutations in the precore region of hepatitis B virus DNA in patients with fulminant and severe hepatitis. N Engl J Med 324: 1699-1704.
33. Parekh S, Zoulim F, Ahn SH, Tsai A, Li J, Kawai S, Khan N, Trpo C, Wands J, Tong S. 2003. Genome replication, virion secretion, and e antigen expression of naturally occurring hepatitis B virus core promoter mutants. J Virol 77: 6601-6612.
34. Park JH. 2004a. [Hepatitis B virus surface antigen: A multifaceted protein]. Korean J Hepatol 10: 248-259.
35. Park JW. 2004b. Practice guideline for diagnosis and treatment of hepatocellular carcinoma. Korean J Hepatol 10: 88-98.
36. Park JH, Cho EW, Lee YJ, Shin SY, Kim KL. 2000a. Determination of the protective effects of neutralizing anti-hepatitis B virus (HBV) immunoglobulins by epitope mapping with recombinant HBV surface-antigen proteins. Microbiol Immunol 44: 703-710.
37. Park US, Park SK, Lee YI, Park JG. 2000b. Hepatitis B virus-X protein upregulates the expression of p21waf1/cip1 and prolongs G1→S transition via a p53-independent pathway in human hepatoma cells. Oncogene 19: 3384-3394.
38. Preikschat P, Gunther S, Reinhold S, Will H, Budde K, Neumayer HH, Kruger DH, Meisel H. 2002. Complex HBV populations with mutations in core promoter, C gene, and pre-S region are associated with development of cirrhosis in long-term renal transplant recipients. Hepatology 35: 466-477.
39. Sato S, Suzuki K, Akahane Y, Akamatsu K, Akiyama K, Yunomura K, Tsuda F, Tanaka T, Okamoto H, Miyakawa Y, Mayumi M. 1995. Hepatitis B virus strains with mutations in the core promoter in patients with fulminant hepatitis. Ann Intern Med 122: 241-248.
40. Scaglioni PP, Melegari M, Wands JR. 1997. Biologic properties of hepatitis B viral genomes with mutations in the precore promoter and precore open reading frame. Virology 233: 374-381.
41. Sirma H, Giannini C, Poussin K, Paterlini P, Kremsdorf D, Brchot C. 1999. Hepatitis B virus X mutants, present in hepatocellular carcinoma tissue abrogate both the antiproliferative and transactivation effects of HBx. Oncogene 18: 4848-4859.
42. Su IJ, Wang HC, Wu HC, Huang WY. 2008. Ground glass hepatocytes contain pre-S mutants and represent preneoplastic lesions in chronic hepatitis B virus infection. J Gastroenterol Hepatol 23: 1169-1174.
43. Tanaka Y, Mukaide M, Orito E, Yuen M, Ito K, Kurbanov F, Sugauchi F, Asahina Y, Izumi N, Kato M, Lai C, Ueda R, Mizokami M. 2006. Specific mutations in enhancer II/core promoter of hepatitis B virus subgenotypes C1/C2 increase the risk of hepatocellular carcinoma. J Hepatol 45: 646-653.
44. Ueno S, Tanabe G, Nuruki K, Hamanoue M, Komorizono Y, Oketani M, Hokotate H, Inoue H, Baba Y, Imamura Y, Aikou T. 2002. Prognostic performance of the new classification of primary liver cancer of Japan (4th edition) for patients with hepatocellular carcinoma: A validation analysis. Hepatol Res 24: 395-403.
45. Wang Y, Chen P, Wu X, Sun AL, Wang H, Zhu YA, Li ZP. 1990. A new enhancer element, ENII, identified in the X gene of hepatitis B virus. J Virol 64: 3977-3981.
46. Yeh CT, So M, Ng J, Yang HW, Chang ML, Lai MW, Chen TC, Lin CY, Yeh TS, Lee WC. 2010. Hepatitis B virus-DNA level and basal core promoter A1762T/G1764A mutation in liver tissue independently predict postoperative survival in hepatocellular carcinoma. Hepatology 52: 1922-1933.
47. Yeung P, Wong DK, Lai C, Fung J, Seto W, Yuen M. 2011. Association of hepatitis B virus pre-S deletions with the development of hepatocellular carcinoma in chronic hepatitis B. J Infect Dis 203: 646-654.
48. Yu MC, Yuan JM, Govindarajan S, Ross RK. 2000. Epidemiology of hepatocellular carcinoma. Can J Gastroenterol 14: 703-709.
49. Yuan J, Zhou B, Tanaka Y, Kurbanov F, Orito E, Gong Z, Xu L, Lu J, Jiang X, Lai W, Mizokami M. 2007. Hepatitis B virus (HBV) genotypes/subgenotypes in China: Mutations in core promoter and precore/core and their clinical implications. J Clin Virol 39: 87-93.
50. Yuen MF, Tanaka Y, Shinkai N, Poon RT, But DY, Fong DY, Fung J, Wong DK, Yuen JC, Mizokami M, Lai CL. 2008. Risk for hepatocellular carcinoma with respect to hepatitis B virus genotypes B/C, specific mutations of enhancer II/core promoter/precore regions and HBV DNA levels. Gut 57: 98-102.